Accent Microcell Limited has released its audited financial results for the half year and financial year ended March 31, 2026. The company reported a total income from operations of ₹35579.95 lakh for the financial year 2025-26, compared to ₹27098.54 lakh in the previous year. Net profit for the year after tax stood at ₹4385.86 lakh, an increase from ₹3306.29 lakh in the corresponding period of the previous year.

Financial Performance

The board of directors approved the financial results at their meeting held on May 12, 2026. For the half year ended March 31, 2026, the company recorded a total income from operations of ₹21383.24 lakh and a net profit of ₹2578.03 lakh. Earnings per share (EPS) for the full year increased to ₹18.65 from ₹14.91 in the previous year.

Dividend Declaration

The Board of Directors has recommended a final dividend of ₹1.00 (10%) per paid-up equity share of the face value of ₹10 each for the financial year 2025-26. This dividend is subject to the approval of the shareholders.

Capital Raise and Utilization

During the year ended March 31, 2026, the company issued 29,46,020 equity shares via a rights issue at an issue price of ₹135 per share, aggregating to ₹3977.13 lakh. The proceeds were primarily allocated for setting up a manufacturing plant for Microcrystalline Cellulose. Additionally, the company had previously raised ₹7840.00 Lakhs through an IPO, with funds utilized for setting up plants for manufacturing Crosacmellose Sodium (CCS), Sodium Starch Glycolate (SSG), and Caboxymethylcellulose (CMC).

Operational Updates and Future Outlook

Management provided an update on Unit 3 during the earnings conference call held on May 16, 2026. Phase 1 of Unit 3, with a capacity of 2,400 metric tons, is expected to commence commercial production by June 25, 2026, pending regulatory approvals including GPCV and pollution control licenses. The delay was attributed to external factors such as abnormal monsoons and licensing requirements. Phase 2, which will cater to MCC production, is expected to go live in March 2027. The company has purchased land for up to Phase 6, with Phase 3 tentatively planned for 2028.

The company reported a total sales volume of 15,000 metric tons in FY26, comprising approximately 70% manufacturing and 30% trading volumes. Export revenue increased to 63% of total sales from 53% in the previous year. Management indicated that blended profit margins are expected to increase by 2-3% with the commercialization of premium products like MCC Spheres and CCS.

Accent Microcell Limited has formally notified the National Stock Exchange of India Limited of a delay in the scheduled implementation of trial run and commercial production at its Unit-III facility, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation, dated 13.05.2026, outlines the external circumstances that have caused the timeline to deviate from that stated in the company's Draft Red Herring Prospectus (DRHP).

Reasons Behind the Delay

Accent Microcell has cited two primary factors responsible for the delay at its Unit-III plant located at Nayka, District Kheda:

• Continuous two abnormal monsoon seasons, which disrupted construction and operational timelines at the facility.
• Unexpected challenges in liaising activities required to obtain various regulatory approvals from the concerned authorities.

These external circumstances collectively pushed the implementation schedule beyond the timelines originally communicated in the DRHP.

Pending Regulatory Approvals for Unit-III

The company has disclosed the current status of approvals that remain outstanding for Unit-III. The following key clearances are yet to be received:

Accent Microcell has stated that it is in continuous coordination with the relevant authorities to ensure these approvals are received at the earliest possible date.

Management's Position

The company's management has conveyed that it is striving continuously to commence the trial run and commercial production at Unit-III upon receiving the requisite approvals. No revised timeline or specific date for the commencement of operations has been disclosed in the intimation.

The disclosure was signed by Hiral Gajera, Company Secretary and Compliance Officer (M.No.: A48107), on behalf of Accent Microcell Limited. The company currently operates Unit-1 at Pirana Plant, Ahmedabad, and Unit-2 at Dahej SEZ, Bharuch, in Gujarat.